文章核心观点 - 公司在2024年第二季度取得了重大进展,包括与Takeda签署了ACI-24.060的独家许可协议,获得1亿美元的预付款,并有机会获得最高21亿美元的里程碑付款[2][3][5] - 公司的多个临床和临床前项目进展顺利,包括阿尔茨海默病疫苗ACI-24.060的ABATE II期试验、帕金森病疫苗ACI-7104.056的II期试验以及NLRP3抑制剂ACI-19764的前期研究[5][7][8][11][12] - 公司在2024年第二季度的现金余额为1.752亿瑞士法郎,其中9230万瑞士法郎来自Takeda的付款,预计可维持公司运营3年[13] 根据目录分别总结 财务状况 - 公司2024年6月30日的现金余额为1.752亿瑞士法郎,包括5160万瑞士法郎的现金和现金等价物以及1.236亿瑞士法郎的短期金融资产[13] - 公司的现金余额预计可维持公司运营3年,前提是收到与ACI-35.030入组目标相关的2460万瑞士法郎里程碑付款,且没有其他里程碑付款[13] - 公司2024年第二季度的合同收入为70万瑞士法郎,主要来自与Takeda的合作[13] - 公司2024年第二季度的研发支出为1710万瑞士法郎,较2023年同期增加,主要是由于VacSYn II期试验和ABATE试验的活动增加[13] - 公司2024年第二季度的管理费用增加90万瑞士法郎至460万瑞士法郎,主要是由于业务发展和许可活动相关的法律费用以及股权激励费用的增加[13] 临床和临床前项目进展 - ACI-24.060 ABATE II期阿尔茨海默病疫苗试验入组进展顺利[7] - ACI-7104.056 VacSYn II期帕金森病疫苗试验预计在2024年下半年获得安全性和免疫原性的中期数据[8] - NLRP3抑制剂ACI-19764在前期研究中显示出良好的疗效和安全性,公司计划尽快提交IND申请[5] - 公司的其他临床前项目,如TDP-43 PET探针和α-突触核蛋白PET探针也在有序推进[11][12] 合作和里程碑 - 公司与Takeda签署了ACI-24.060的独家许可协议,获得1亿美元的预付款,并有机会获得最高21亿美元的里程碑付款[5] - 公司董事会和管理层在第二季度增持了公司股票[6]

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating claims on behalf of investors in R1 RCM Inc. (NASDAQ:RCM) concerning the acquisition of R1 RCM by its significant shareholder, TowerBrook Capital Partners L.P. Under the terms of the acquisition, R1 RCM shareholders would receive $14.30 per share in cash. According to Wolf Popper partner Carl Stine, "The deal price of $14.30 per share seems unfairly low. It is significantly below R1 RCM's 52-week high stock price of $18.54 per shar ...

The SEED-Eisai Research Collaboration leverages Eisai's leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of up to $1.5 billion plus tiered royalties upon Eisai's exercise of their exclusive rights under the strategic research collaboration Concurrently, SEED has launched Series A-3 financing with a first close of $24 million from investors led by Eisai. A second close is targeted for Q4 2024 The Series A-3 financing will advance clinical developme ...

Beamr Issues Q2-2024 CEO Letter to Shareholders and Announces its First Half 2024 Financial Results Herzliya, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video optimization technology and solutions, today issued a Letter to Shareholders from Sharon Carmel, Chief Executive Officer, including its financial results for the six months ended June 30, 2024. Dear Shareholders: I am pleased to update you on our Q2-2024 activities and progress, which include significant de ...

Semi-Live Focal One Procedure to be Conducted on August 15th at 5:00 pm (KST) LYON, France, August 6, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced that the Company's leading robotic HIFU technology platform, Focal One, will be featured at the 41st World Congress of Endourology and Uro-Technology (WCET 2024) meeting, taking place in Seoul, South Korea, from August 12-16, 2024. "Our leading Focal One platform continues to generate strong interest from ...

PHILADELPHIA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinicalstage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity 44th Annual Growth Conference Format: Management will participate in a presentation and investor meetings Date: Tuesday, August 13, 2024 Presentation Time: 8:00 a.m. ET Location: Boston, MA 15th Ann ...

SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference c ...

PLANO, Texas, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Today, European Wax Center, Inc. (NASDAQ:EWCZ) (the "Company" or "European Wax Center"), the largest and fastest-growing franchisor and operator of out-of-home waxing services in the United States, announced the appointment of Julia Hunter to its Board of Directors ("Board"), effective August 1, 2024. Ms. Hunter will serve on the Nominating and Governance committee. Ms. Hunter joins the European Wax Center Board currently serving as the CEO of luxury Californi ...

LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key European Patent entitled: "Compositions Comprising Chemerin ...

Upon closing, Seres to receive $175M cash infusion, including an upfront payment, prepayment of a future commercial milestone payment, and an equity investment in Seres common stock, less approximately $20M in settlement of net obligations between the Parties; anticipated deal closing in the next 90 days Additional approximately $75M in cash payments are due to Seres in 2025, contingent upon Seres' compliance with transition obligations, with the potential for additional future commercial milestone payments ...